Medtronic reported a 26% decrease in Q4 revenue to $6.0 billion, with GAAP EPS at $0.48 and non-GAAP EPS at $0.58. The results were in line with previous updates, reflecting the impact of deferred procedures due to the COVID-19 pandemic. Despite the challenges, the company increased its dividend, showcasing its financial strength.
Q4 revenue decreased by 26% as reported and 25% organically, reaching $6.0 billion.
GAAP diluted EPS was $0.48, while non-GAAP diluted EPS was $0.58.
The company's financial results aligned with the update provided on April 21, reflecting the broad impact on the MedTech industry.
Medtronic increased its quarterly dividend to $0.58, marking the 43rd consecutive year of dividend increases.
Due to the uncertainty caused by the COVID-19 pandemic, Medtronic is not providing formal annual or quarterly financial guidance at this time.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance